Annovis Bio is seeking orphan drug status for its investigational therapy ANVS401, known as Posiphen, for treating Alzheimer’s disease in people with Down syndrome (DS-AD). The clinical-stage drug platform company has filed an application with the U.S. Food and Drug Administration (FDA) for such designation, granted to therapies for rare diseases. “The FDA orphan drug application for ANVS401 to treat DS-AD is an important milestone for Annovis as we focus on building a robust product pipeline…
You must be logged in to read/download the full post.
The post Annovis Seeks Orphan Drug Status for ANVS401 for Down Syndrome Patients appeared first on BioNewsFeeds.